Correlation between HLA allele risk and drug patch test result in cutaneous adverse drug reaction

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20241119002

Enrollment

Registered

2024-11-19

Start date

2023-12-11

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous drug allergy patients Drug patch test, cutaneous drug allergy, HLA allele.

Interventions

Cutaneous allergic patients will receive both patch test and HLA allele test result

No Intervention Other

Patch test and HLA allele test

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >= 20 years olds, 2. Diagnosed cutaneous drug allergy by dermatologists, 3.naranjo score>=4, 4. Agree to perform patch test and HLA test

Exclusion criteria

Exclusion criteria: 1. History allergy to any topical drugs, 2. Pregnancy, 3. History of dermatitis of infection at back or buttock, 4. History of taking immunosuppressive drugs; if prednisolone dosage more than 15 mg/day, more than 3 weeks.

Design outcomes

Primary

Measure	Time frame
Patch test result 5 days HLA allele risk in Positive patch test result (Redness in patch test) compared with HLA allele risk in patch test negative results in cutaneous drug allergy patients.	—

Secondary

Measure	Time frame
HLA allele risk 3 months HLA allele sequencing in cutaneous allergy patient in specific drugs	—

Countries

Thailand

Contacts

Public ContactRujira Leetanaporn

Phramongkutklao hospital

Nunglinglee@gmail.com0922843886

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026